Phase 2a Study in Healthy Adult Participants Pre-treated With INNA-051 and Challenged With Influenza Virus
Latest Information Update: 14 Nov 2023
At a glance
- Drugs INNA-051 (Primary)
- Indications Influenza virus infections
- Focus Proof of concept; Therapeutic Use
- Sponsors Ena Respiratory
- 11 Sep 2023 Results presented in an Ena Respiratory Media Release.
- 13 Feb 2023 Results published in the Ena Respiratory Media Release
- 17 Jan 2023 Status changed from recruiting to completed.